ISRCTN16227145Completed未知
A randomized, controlled, double-blind, double-dummy clinical trial to evaluate the safety and efficacy of Loxoprofen Sodium Cataplasm ointment (Loxonin;PAP100mg) against myalgia
ead Chemical Co. Ltd (Japan)0 sites160 target enrollmentStarted: December 29, 2014Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 160
Study Overview
Brief Summary
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/30725315
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Age: > 18 years, < 80 years, 18 and 80 years included
- •2. Either sex
- •3. Any of the following with moderate intensity: resting pain, pressing pain, exercising pain
- •4. The patients were not treated by drugs for one week before giving the investigational product, and no change in physiotherapy for 2 weeks during the first treatment.
- •5. Patients agree to participate in the trial and sign informed content form after completely understanding the contents of the clinical trial
Exclusion Criteria
- •1. Patient's pain caused by external injury and diagnosed as acute
- •2. Patient's pain diagnosed as neurosis
- •3. Patients with lesions, poor skin conditions on pasting site, or with cutaneous anaphylaxis
- •4. Patients who need steroid drugs or other non-steroid analgesics which may interfere the therapeutic method in this clinical trial.
- •5. Patient with peptic ulcer.
- •6. Patients with bronchial asthma.
- •7. Patients with serious cardiac diseases, hepatic diseases (ALT, AST are equal or bigger than 2.5 times of upper limit), renal diseases (creatinine is equal or bigger than 1.5 times of upper limit), hematologic disease, diabetes, mental diseases, and other serious complications.
- •8. Pregnant women, lactating mothers or patients who have the possibility of pregnancy, and want to be pregnant during the trial.
- •9. Patient allergic to this drug.
- •10. Patients participating any clinical trials on investigational drug or marketed drug within 3 months before enrollment or during clinical trial
- •11. Other patients judged to be inappropriate for this clinical trial by the investigator
Investigators
Similar Trials
Completed
Not Applicable
PREVAIL study - PREVenting infection using Antimicrobial Impregnated Long linesInfectious disease, preterm babies requiring a PICCNeonatal DiseasesISRCTN81931394Great Ormond Street Hospital for Children NHS Foundation Trust (UK)861
Completed
Not Applicable
Studying the impact of Doxycycline on fear memory in healthy individualsISRCTN66987216Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)160
Completed
Phase 2
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitisISRCTN53663626ChemoCentryx, Inc. (USA)60
Completed
Not Applicable
A placebo controlled pilot study to explore the affects of GABA tea on children with autistic spectrum conditionsAutism Spectrum ConditionsMental and Behavioural DisordersISRCTN72571312Coventry University9
Active, not recruiting
Phase 2
A phase II trial of Cediranib in the treatment of patients with Alveolar Soft Part SarcomaSarcomaCancerAlveolar soft part sarcomaISRCTN63733470The Institute of Cancer Research/Royal Marsden Hospital NHS Foundation Trust (UK)48